论文部分内容阅读
目的探讨参附注射液对缓慢心律失常的临床治疗作用及不良反应发生机制。方法收集47例缓慢心律失常伴随心脏低排血量症状患者使用参附注射液及其他药物治疗患者临床资料。将参附注射液组患者作为观察组,其他药物治疗作为对照组,观察组使用参附注射液40 ml静脉滴注,1次/d;对照组根据患者心动过缓的程度使用阿托品、异丙肾上腺素等药物治疗,观察两组治疗前后心率改变、胸闷气短、心悸等临床症状改善情况;收集观察组和对照组患者的不良反应发生频次、发生类型及分析其不良反应可能的机制。结果观察组总有效率为84.62%,对照组为85.71%,两组患者总有效率比较差异无统计学意义(P>0.05)。但两组不良反应发生率观察组低于对照组,观察组不良反应4例,不良反应率15.38%;对照组不良反应7例,不良反应率33.33%,两组患者不良反应率比较,差异有统计学意义(P<0.05)。结论参附注射液对各种窦性心动过缓患者均有治疗作用,且不良反应发生率更低。
Objective To investigate the clinical therapeutic effect of Shenfu injection on patients with bradyarrhythmia and the mechanism of adverse reactions. Methods The clinical data of 47 cases of patients with slow arrhythmia accompanied by low cardiac output of cardiac paracentesis and other drugs were collected. The patients in Shenfu injection group were taken as the observation group and the other drugs were taken as the control group. The observation group was treated with 40 ml Shenfu injection once a day, while the control group was given atropine according to the degree of bradycardia. Epinephrine and other drugs. The changes of heart rate, chest tightness and shortness of breath, palpitations and other clinical symptoms were observed before and after treatment. The occurrence frequency, occurrence type and possible mechanism of adverse reactions in the observation group and the control group were collected. Results The total effective rate was 84.62% in the observation group and 85.71% in the control group. There was no significant difference in the total effective rate between the two groups (P> 0.05). However, the adverse reaction rate of the two groups was lower than that of the control group, 4 cases of adverse reactions in the observation group, the adverse reaction rate was 15.38%; 7 cases of adverse reactions in the control group, the adverse reaction rate was 33.33% Statistical significance (P <0.05). Conclusion Shenfu injection has therapeutic effect on all kinds of sinus bradycardia and the incidence of adverse reactions is lower.